

Naoyuki Uchida

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/455786/publications.pdf>

Version: 2024-02-01

103
papers

1,839
citations

279798

23
h-index

330143

37
g-index

104
all docs

104
docs citations

104
times ranked

1745
citing authors

#	ARTICLE	IF	CITATIONS
1	Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2008-2016.	2.0	153
2	Comparison of Outcomes of 8/8 and 7/8 Allele-Matched Unrelated Bone Marrow Transplantation and Single-Unit Cord Blood Transplantation in Adults with Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 330-338.	2.0	100
3	High incidence of haemophagocytic syndrome following umbilical cord blood transplantation for adults. <i>British Journal of Haematology</i> , 2009, 147, 543-553.	2.5	89
4	Umbilical Cord Blood Transplantation after Reduced-Intensity Conditioning for Elderly Patients with Hematologic Diseases. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 583-590.	2.0	84
5	Comparison of transplant outcomes from matched sibling bone marrow or peripheral blood stem cell and unrelated cord blood in patients 50 years or older. <i>American Journal of Hematology</i> , 2016, 91, E284-92.	4.1	59
6	A Novel Reduced-Toxicity Myeloablative Conditioning Regimen Using Full-Dose Busulfan, Fludarabine, and Melphalan for Single Cord Blood Transplantation Provides Durable Engraftment and Remission in Nonremission Myeloid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1844-1850.	2.0	52
7	Mycophenolate and Tacrolimus for Graft-Versus-Host Disease Prophylaxis for Elderly After Cord Blood Transplantation: A Matched Pair Comparison With Tacrolimus Alone. <i>Transplantation</i> , 2011, 92, 366-371.	1.0	51
8	Effect of cytogenetic risk status on outcomes for patients with acute myeloid leukemia undergoing various types of allogeneic hematopoietic cell transplantation: an analysis of 7812 patients. <i>Leukemia and Lymphoma</i> , 2018, 59, 601-609.	1.3	51
9	Successful sustained engraftment after reduced-intensity umbilical cord blood transplantation for adult patients with severe aplastic anemia. <i>Blood</i> , 2011, 117, 3240-3242.	1.4	49
10	Impact of HLA disparity in the graft-versus-host direction on engraftment in adult patients receiving reduced-intensity cord blood transplantation. <i>Blood</i> , 2009, 114, 1689-1695.	1.4	44
11	Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups. <i>Haematologica</i> , 2016, 101, 1592-1602.	3.5	41
12	Unit selection for umbilical cord blood transplantation for adults with acute myeloid leukemia in complete remission: a Japanese experience. <i>Bone Marrow Transplantation</i> , 2019, 54, 1789-1798.	2.4	39
13	Improvement of early mortality in single-unit cord blood transplantation for Japanese adults from 1998 to 2017. <i>American Journal of Hematology</i> , 2020, 95, 343-353.	4.1	39
14	Impact of total body irradiation on successful neutrophil engraftment in unrelated bone marrow or cord blood transplantation. <i>American Journal of Hematology</i> , 2017, 92, 171-178.	4.1	38
15	Prognostic factors for adult single cord blood transplantation among European and Japanese populations: the Eurocord/ALWP-EBMT and JSHCT/JDCHCT collaborative study. <i>Leukemia</i> , 2020, 34, 128-137.	7.2	36
16	Anti-HLA Antibodies Other than Against HLA-A, -B, -DRB1 Adversely Affect Engraftment and Nonrelapse Mortality in HLA-Mismatched Single Cord Blood Transplantation: Possible Implications of Unrecognized Donor-specific Antibodies. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1634-1640.	2.0	35
17	Comparison of Conditioning with Fludarabine/Busulfan and Fludarabine/Melphalan in Allogeneic Transplantation Recipients 50 Years or Older. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2079-2087.	2.0	34
18	Impact of HLA Allele Mismatch at HLA-A, -B, -C, and -DRB1 in Single Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 519-528.	2.0	34

#	ARTICLE	IF	CITATIONS
19	Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Cancer Science</i> , 2019, 110, 3255-3266.	3.9	32
20	Relapse of acute myeloid leukemia after allogeneic hematopoietic cell transplantation: clinical features and outcomes. <i>Bone Marrow Transplantation</i> , 2021, 56, 1126-1133.	2.4	27
21	Allogeneic unrelated bone marrow transplantation from older donors results in worse prognosis in recipients with aplastic anemia. <i>Haematologica</i> , 2016, 101, 644-652.	3.5	26
22	Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia conducted in Japan during the past quarter century. <i>Annals of Hematology</i> , 2020, 99, 1351-1360.	1.8	26
23	Granulocyte colony-stimulating factor combined regimen in cord blood transplantation for acute myeloid leukemia: a nationwide retrospective analysis in Japan. <i>Haematologica</i> , 2014, 99, e264-e268.	3.5	25
24	Impacts of thymoglobulin in patients with acute leukemia in remission undergoing allogeneic HSCT from different donors. <i>Blood Advances</i> , 2019, 3, 105-115.	5.2	25
25	Clinical and Microbiological Characteristics of Breakthrough Candidemia in Allogeneic Hematopoietic Stem Cell Transplant Recipients in a Japanese Hospital. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	23
26	Comparison of Autologous and Unrelated Transplants for Cytogenetically Normal Acute Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1447-1454.	2.0	23
27	Single Cord Blood Transplantation Versus Unmanipulated Haploidentical Transplantation for Adults with Acute Myeloid Leukemia in Complete Remission. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 334.e1-334.e11.	1.2	23
28	Off-the-shelf bone marrow-derived mesenchymal stem cell treatment for acute graft-versus-host disease: real-world evidence. <i>Bone Marrow Transplantation</i> , 2021, 56, 2355-2366.	2.4	23
29	Prognostic Impact of Donor Source on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in Adults with Chronic Myelomonocytic Leukemia: A Nationwide Retrospective Analysis in Japan. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 840-848.	2.0	21
30	Mycophenolate mofetil use after unrelated hematopoietic stem cell transplantation for prophylaxis and treatment of graft-versus-host disease in adult patients in Japan. <i>Clinical Transplantation</i> , 2014, 28, 980-989.	1.6	20
31	Allogeneic haematopoietic cell transplantation with reduced-intensity conditioning for elderly patients with advanced myelodysplastic syndromes: a nationwide study. <i>British Journal of Haematology</i> , 2015, 168, 463-466.	2.5	20
32	Additional Cytogenetic Abnormalities with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia on Allogeneic Stem Cell Transplantation in the Tyrosine Kinase Inhibitor Era. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2009-2016.	2.0	19
33	Clinical practice recommendations for the diagnosis and management of human herpesvirus-6B encephalitis after allogeneic hematopoietic stem cell transplantation: the Japan Society for Hematopoietic Cell Transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 1004-1013.	2.4	19
34	Updated Comparison of 7/8 HLA Allele-Matched Unrelated Bone Marrow Transplantation and Single-Unit Umbilical Cord Blood Transplantation as Alternative Donors in Adults with Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2105-2114.	2.0	17
35	Comparison of the outcomes after haploidentical and cord blood salvage transplantations for graft failure following allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 1784-1795.	2.4	17
36	The outcome and characteristics of patients with relapsed adult T cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation. <i>Hematological Oncology</i> , 2019, 37, 54-61.	1.7	16

#	ARTICLE	IF	CITATIONS
37	Comparing cord blood transplantation and matched related donor transplantation in non-remission acute myeloid leukemia. <i>Leukemia</i> , 2022, 36, 1132-1138.	7.2	16
38	Improved trends in survival and engraftment after single cord blood transplantation for adult acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2022, 12, .	6.2	16
39	Rapid T cell chimerism switch and memory T cell expansion are associated with pre-engraftment immune reaction early after cord blood transplantation. <i>British Journal of Haematology</i> , 2013, 160, 255-258.	2.5	14
40	Outcome of Second Transplantation Using Umbilical Cord Blood for Graft Failure after Allogeneic Hematopoietic Stem Cell Transplantation for Aplastic Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2137-2142.	2.0	14
41	Differential Effect of Graft-versus-Host Disease on Survival in Acute Leukemia according to Donor Type. <i>Clinical Cancer Research</i> , 2021, 27, 4825-4835.	7.0	14
42	Reduced-intensity conditioning is a reasonable alternative for Philadelphia chromosome-positive acute lymphoblastic leukemia among elderly patients who have achieved negative minimal residual disease: a report from the Adult Acute Lymphoblastic Leukemia Working Group of the JSHCT. <i>Bone Marrow Transplantation</i> , 2020, 55, 1317-1325.	2.4	14
43	Comparison of Autologous Hematopoietic Cell Transplantation and Chemotherapy as Postremission Treatment in Non-M3 Acute Myeloid Leukemia in First Complete Remission. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 444-451.	0.4	13
44	Risk Assessment in Adult T Cell Leukemia/Lymphoma Treated with Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 832-839.	2.0	13
45	Increased opportunity for prolonged survival after allogeneic hematopoietic stem cell transplantation in patients aged 60-69 years with myelodysplastic syndrome. <i>Annals of Hematology</i> , 2019, 98, 1367-1381.	1.8	13
46	Impact of graft-versus-host disease and graft-versus-leukemia effect based on minimal residual disease in Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>British Journal of Haematology</i> , 2020, 190, 84-92.	2.5	13
47	Predicting non-relapse mortality following allogeneic hematopoietic cell transplantation during first remission of acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2021, 56, 387-394.	2.4	13
48	Time-Varying Effects of Graft Type on Outcomes for Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 307-315.	2.0	12
49	Breakthrough viridans streptococcal bacteremia in allogeneic hematopoietic stem cell transplant recipients receiving levofloxacin prophylaxis in a Japanese hospital. <i>BMC Infectious Diseases</i> , 2016, 16, 372.	2.9	11
50	Effects of Haplotype Matching on Outcomes after Adult Single-Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 509-518.	2.0	11
51	Outcome and Risk Factors for Therapy-Related Myeloid Neoplasms Treated with Allogeneic Stem Cell Transplantation in Japan. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1543-1551.	2.0	10
52	The impact of graft cell source on bloodstream infection in the first 100 days after allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 1625-1634.	2.4	10
53	Minimal residual disease (MRD) positivity at allogeneic hematopoietic cell transplantation, not the quantity of MRD, is a risk factor for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>International Journal of Hematology</i> , 2021, 113, 832-839.	1.6	9
54	Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome in adolescent and young adult patients. <i>Bone Marrow Transplantation</i> , 2021, 56, 2510-2517.	2.4	9

#	ARTICLE	IF	CITATIONS
55	Prognostic value of measurable residual disease at allogeneic transplantation for adults with core binding factor acute myeloid leukemia in complete remission. <i>Bone Marrow Transplantation</i> , 2021, 56, 2779-2787.	2.4	9
56	Myeloablative intravenous busulfan-containing regimens for allo-HSCT in AML or MDS patients over 54 years old: combined results of three phase II studies. <i>International Journal of Hematology</i> , 2020, 112, 510-523.	1.6	8
57	Favorable Effect of Cytomegalovirus Reactivation on Outcomes in Cord Blood Transplant and Its Differences Among Disease Risk or Type. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1363-1370.	2.0	8
58	The impact of GVHD on outcomes after adult single cord blood transplantation in European and Japanese populations. <i>Bone Marrow Transplantation</i> , 2022, 57, 57-64.	2.4	8
59	Possible graft-versus-host disease involving the central nervous system soon after cord blood transplantation. <i>American Journal of Hematology</i> , 2009, 84, 764-766.	4.1	7
60	Long-term results of reduced-intensity conditioning allogeneic hematopoietic cell transplantation for older patients with acute myeloid leukemia: a retrospective analysis of 10-year follow-up data. <i>Bone Marrow Transplantation</i> , 2020, 55, 2008-2016.	2.4	7
61	Reduced leukemia relapse through cytomegalovirus reactivation in killer cell immunoglobulin-like receptor-ligand-mismatched cord blood transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 1352-1363.	2.4	7
62	Comparison of fludarabine, a myeloablative dose of busulfan, and melphalan vs conventional myeloablative conditioning regimen in patients with relapse and refractory acute myeloid leukemia in non-remission status. <i>Bone Marrow Transplantation</i> , 2021, 56, 2302-2304.	2.4	7
63	Splenomegaly Negatively Impacts Neutrophil Engraftment in Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1689-1696.	2.0	6
64	Characteristics of gram-negative bacteremia during febrile neutropenia among allogeneic hematopoietic stem cell transplant recipients on levofloxacin prophylaxis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 941-948.	2.9	6
65	Single cord blood transplantation for acute myeloid leukemia patients aged 60 years or older: a retrospective study in Japan. <i>Annals of Hematology</i> , 2021, 100, 1849-1861.	1.8	6
66	Severe acute graft-versus-host disease increases the incidence of blood stream infection and mortality after allogeneic hematopoietic cell transplantation: Japanese transplant registry study. <i>Bone Marrow Transplantation</i> , 2021, 56, 2125-2136.	2.4	6
67	The impacts of BCR-ABL1 mutations in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation. <i>Annals of Hematology</i> , 2020, 99, 2393-2404.	1.8	5
68	Outcomes of third allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute leukemia after a second transplantation. <i>Bone Marrow Transplantation</i> , 2022, 57, 43-50.	2.4	5
69	Autologous hematopoietic cell transplantation during second or subsequent complete remission of acute promyelocytic leukemia: a prognostic factor analysis. <i>Bone Marrow Transplantation</i> , 2022, 57, 78-82.	2.4	5
70	Disease-specific impact of anti-thymocyte globulin in allogeneic hematopoietic cell transplantation: a nationwide retrospective study on behalf of the JSTCT, transplant complications working group. <i>Bone Marrow Transplantation</i> , 2022, 57, 479-486.	2.4	5
71	Risk and Predictive Factors for Candidemia After Allogeneic Hematopoietic Cell Transplantation: JSTCT Transplant Complications Working Group. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 209.e1-209.e9.	1.2	5
72	Autologous or allogeneic hematopoietic cell transplantation for relapsed or refractory PTCL-NOS or AITL. <i>Leukemia</i> , 2022, 36, 1361-1370.	7.2	5

#	ARTICLE	IF	CITATIONS
73	Reduced-intensity stem cell transplantation for acute myeloid leukemia with fludarabine-based conditioning with intravenous busulfan versus melphalan. <i>Bone Marrow Transplantation</i> , 2020, 55, 1955-1965.	2.4	4
74	Adding melphalan to fludarabine and a myeloablative dose of busulfan improved survival after allogeneic hematopoietic stem cell transplantation in a propensity score-matched cohort of hematological malignancies. <i>Bone Marrow Transplantation</i> , 2021, 56, 1691-1699.	2.4	4
75	Impact of conditioning intensity and regimen on transplant outcomes in patients with adult T-cell leukemia-lymphoma. <i>Bone Marrow Transplantation</i> , 2021, 56, 2964-2974.	2.4	4
76	Outcome of allogeneic hematopoietic stem cell transplantation for follicular lymphoma relapsing after autologous transplantation: analysis of the Japan Society for Hematopoietic Cell Transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 1462-1466.	2.4	4
77	Impact of High-Frequency HLA Haplotypes on Clinical Cytomegalovirus Reactivation in Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2482-2489.	2.0	3
78	HLA discrepancy between graft and host rather than that graft and first donor impact the second transplant outcome. <i>Haematologica</i> , 2019, 104, 1055-1061.	3.5	3
79	<i>Stenotrophomonas maltophilia</i> bloodstream infections in adult recipients of umbilical cord blood transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 269.e1-269.e7.	1.2	3
80	Comparison of immunosuppressant regimens in salvage cord blood transplantation for graft failure after allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 400-410.	2.4	3
81	Prognostic significance of lymphocyte reconstitution in the early phase after cord blood transplantation. <i>British Journal of Haematology</i> , 2021, 193, 423-427.	2.5	3
82	Prognostic factors in salvage transplantation for graft failure following allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2183-2193.	2.4	3
83	Impact of the combination of donor age and HLA disparity on the outcomes of unrelated bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2410-2422.	2.4	3
84	Prognostic Impact of Cytogenetic Evolution on the Outcome of Allogeneic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia in Nonremission: A Single-Institute Analysis of 212 Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2262-2270.	2.0	3
85	Comparison of reduced-intensity/toxicity conditioning regimens for umbilical cord blood transplantation for lymphoid malignancies. <i>Bone Marrow Transplantation</i> , 2020, 55, 2098-2108.	2.4	3
86	HHV-6 associated diseases are one of the major factors on higher early CNS complications in CB recipients than in those of BM/PBSC. <i>Bone Marrow Transplantation</i> , 2021, 56, 686-688.	2.4	2
87	Personalized prediction of overall survival in patients with AML in non-complete remission undergoing allo-HCT. <i>Cancer Medicine</i> , 2021, 10, 4250-4268.	2.8	2
88	Newly proposed threshold and validation of white blood cell count at diagnosis for Philadelphia chromosome-positive acute lymphoblastic leukemia: risk assessment of relapse in patients with negative minimal residual disease at transplantation—a report from the Adult Acute Lymphoblastic Leukemia Working Group of the JSTCT. <i>Bone Marrow Transplantation</i> , 2021, 56, 2842-2848.	2.4	2
89	Pretransplantation Red Blood Cell and Platelet Transfusion Burden in De Novo Myelodysplastic Syndrome Undergoing Allogeneic Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 671-678.	1.2	2
90	Syngeneic hematopoietic stem cell transplantation for acute myeloid leukemia: a propensity score-matched analysis. <i>Blood Cancer Journal</i> , 2021, 11, 159.	6.2	2

#	ARTICLE	IF	CITATIONS
91	Impact of HLA disparity on the risk of overall mortality in patients with grade II–IV acute GVHD on behalf of the HLA Working Group of Japan Society for Hematopoietic Cell Transplantation. Bone Marrow Transplantation, 2021, 56, 2990-2996.	2.4	2
92	Altered effect of killer immunoglobulin-like receptor–ligand mismatch by graft versus host disease prophylaxis in cord blood transplantation. Bone Marrow Transplantation, 2021, 56, 3059-3067.	2.4	2
93	Characterization of myeloid neoplasms following allogeneic hematopoietic cell transplantation. American Journal of Hematology, 2021, , .	4.1	2
94	Impact of donor types on reduced-intensity conditioning allogeneic stem cell transplant for mature lymphoid malignancies. Bone Marrow Transplantation, 2022, 57, 243-251.	2.4	2
95	HLA 1–3 antigen–mismatched related peripheral blood stem cells transplantation using low-dose antithymocyte globulin versus unrelated cord blood transplantation. American Journal of Hematology, 2022, 97, 311-321.	4.1	2
96	Improved outcomes of single-unit cord blood transplantation for acute myeloid leukemia by killer immunoglobulin-like receptor 2DL1-ligand mismatch. Bone Marrow Transplantation, 2022, 57, 1171-1179.	2.4	2
97	Prospective Multicenter Phase II Study of Myeloablative Conditioning Consisted of Intravenous Busulfan and Fludarabine +/- Total Body Irradiation for Older Patients (55 years and older): Final Analysis of the JSCT FB09 Study. Biology of Blood and Marrow Transplantation, 2014, 20, S253.	2.0	1
98	Does one model fit all? Predicting non-relapse mortality after allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2021, 56, 1720-1722.	2.4	1
99	Prophylactic Foscarnet and Suppression of Pre-Engraftment Immune Reaction Are Essential to Overcome the Development of HHV-6 Encephalitis From the Experience of 496 Adult Cord Blood Transplants in Toranomon Hospital. Blood, 2012, 120, 461-461.	1.4	1
100	Human leukocyte antigen (HLA) haplotype matching in unrelated single HLA allele mismatch bone marrow transplantation. Bone Marrow Transplantation, 2022, 57, 407-415.	2.4	1
101	Oral beclomethasone dipropionate as an initial treatment for stages 1–2 gastrointestinal tract acute graft-versus-host disease following unrelated cord blood transplantation. Annals of Hematology, 2015, 94, 2073-2075.	1.8	0
102	The Future Prospects of Cord Blood Transplantation—A Japanese Perspective—. Journal of Hematopoietic Cell Transplantation, 2021, 10, 58-65.	0.1	0
103	Complications after Cord Blood Transplantation: current and future perspectives. Journal of Illusion, 2022, 11, 81-89.	0.1	0